144 related articles for article (PubMed ID: 11417113)
1. Purine analogs as CDK enzyme inhibitory agents: a survey and QSAR analysis.
Lee AD; Ren S; Lien EJ
Prog Drug Res; 2001; 56():155-93. PubMed ID: 11417113
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
Davies TG; Bentley J; Arris CE; Boyle FT; Curtin NJ; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Hardcastle IR; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Wang L; Whitfield HJ
Nat Struct Biol; 2002 Oct; 9(10):745-9. PubMed ID: 12244298
[TBL] [Abstract][Full Text] [Related]
3. Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors.
Ruetz S; Fabbro D; Zimmermann J; Meyer T; Gray N
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):1-14. PubMed ID: 12678910
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Arris CE; Boyle FT; Calvert AH; Curtin NJ; Endicott JA; Garman EF; Gibson AE; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Lawrie AM; Newell DR; Noble ME; Sausville EA; Schultz R; Yu W
J Med Chem; 2000 Jul; 43(15):2797-804. PubMed ID: 10956187
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future.
Haesslein JL; Jullian N
Curr Top Med Chem; 2002 Sep; 2(9):1037-50. PubMed ID: 12171570
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
Chang YT; Gray NS; Rosania GR; Sutherlin DP; Kwon S; Norman TC; Sarohia R; Leost M; Meijer L; Schultz PG
Chem Biol; 1999 Jun; 6(6):361-75. PubMed ID: 10375538
[TBL] [Abstract][Full Text] [Related]
7. Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.
Otyepka M; Krystof V; Havlícek L; Siglerová V; Strnad M; Koca J
J Med Chem; 2000 Jun; 43(13):2506-13. PubMed ID: 10891109
[TBL] [Abstract][Full Text] [Related]
8. The design and synthesis of purine inhibitors of CDK2. III.
Shum PW; Peet NP; Weintraub PM; Le TB; Zhao Z; Barbone F; Cashman B; Tsay J; Dwyer S; Loos PC; Powers EA; Kropp K; Wright PS; Bitonti A; Dumont J; Borcherding DR
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1067-78. PubMed ID: 11562960
[TBL] [Abstract][Full Text] [Related]
9. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.
Knockaert M; Lenormand P; Gray N; Schultz P; Pouysségur J; Meijer L
Oncogene; 2002 Sep; 21(42):6413-24. PubMed ID: 12226745
[TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR CoMFA on cyclin-dependent kinase inhibitors.
Ducrot P; Legraverend M; Grierson DS
J Med Chem; 2000 Nov; 43(22):4098-108. PubMed ID: 11063606
[TBL] [Abstract][Full Text] [Related]
11. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
12. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
[TBL] [Abstract][Full Text] [Related]
13. Yeast as a model system to screen purine derivatives against human CDK1 and CDK2 kinases.
Mayi T; Facca C; Anne S; Vernis L; Huang ME; Legraverend M; Faye G
J Biotechnol; 2015 Feb; 195():30-6. PubMed ID: 25541464
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Hirai H; Kawanishi N; Iwasawa Y
Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
[TBL] [Abstract][Full Text] [Related]
17. A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.
Gucký T; Jorda R; Zatloukal M; Bazgier V; Berka K; Řezníčková E; Béres T; Strnad M; Kryštof V
J Med Chem; 2013 Aug; 56(15):6234-47. PubMed ID: 23829517
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological properties of C-2, C-8, N-9 substituted 6-(3-chloroanilino)purine derivatives as cyclin-dependent kinase inhibitors. Part II.
Oh CH; Kim HK; Lee SC; Oh C; Yang BS; Rhee HJ; Cho JH
Arch Pharm (Weinheim); 2001 Nov; 334(11):345-50. PubMed ID: 11822171
[TBL] [Abstract][Full Text] [Related]
19. ATP-site directed inhibitors of cyclin-dependent kinases.
Gray N; Détivaud L; Doerig C; Meijer L
Curr Med Chem; 1999 Sep; 6(9):859-75. PubMed ID: 10495356
[TBL] [Abstract][Full Text] [Related]
20. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
David-Pfeuty T
Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
